 |
This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (January 2007) |
 |
|
|
Nicodicodeine
|
|
| Systematic (IUPAC) name | |
| (5α,6α)-3-methoxy- 17-methyl- 4,5-epoxymorphinan- 6-yl nicotinate | |
| Identifiers | |
| CAS number | 808-24-2 |
| ATC code | none |
| PubChem | 5464304 |
| Chemical data | |
| Formula | C24H26N2O4 |
| Mol. mass | 406.474 g/mol |
| Synonyms | 6-Nicotinoyldihydrocodeine |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral, intravenous
|
Nicodicodeine is an opiate derivative developed as a cough suppressant and analgesic. It is not commonly used, but has activity similar to other opiates. Nicodicodeine is metabolised in the liver by demethylation to produce 6-nicotinoyldihydromorphine, and subsequently further metabolised to dihydromorphine. Since the final active metabolite is the slightly stronger opiate dihydromorphine rather than morphine, nicodicodeine can be expected to be marginally more potent and longer acting than nicocodeine. Side effects are similar to those of other opiates and include itching, nausea and respiratory depression.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
